Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...
Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results